NEW YORK, Nov. 3, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth
Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest report, "Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth" that provides key data, information and analysis of the major trends and issues affecting the biomarkers in cancer research. The report provides a comprehensive insight into the history of biomarkers, its uses, efficiency as well as their limitations. The report also provides a detailed analysis of cancer biomarkers market characterization in terms of its market size, segmentation by key cancer types and the major market drivers and barriers. The report also talks about the patent landscape for cancer biomarkers and provides comprehensive analysis. The report also looks into the cancer biomarkers pipeline along with analysis on the pipeline by indication, phase of development and geography of development. The report also provides competitive landscape of the market that profiles key market players along with their brief business description, pipeline, major products and major M&A and partnership deals. The report also provides detailed analysis of major partnership deals that have taken place in the cancer biomarkers market since 2006 along with segmentation by number of deals per year, indication, deal type, geography and companies. In addition, the report also talks about the major M&A deals in the cancer biomarkers market since 2005 along with segmentation by value, geography and companies. Finally, the report provides the major conclusions from the report.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research's team of industry experts.
Scope
The scope of the report includes:
- Detailed overview of biomarkers in pharmaceutical industry along with their use, efficiency and limitation
- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by cancer types including breast cancer, colorectal cancer, prostate cancer, lung cancer, cervical cancer, head and neck cancer, pancreatic cancer, ovarian cancer and stomach cancer
- Key market drivers and restraints shaping the cancer biomarkers market
- Patent analysis of the cancer biomarkers along with segmentation by patent type, company and geography
- Pipeline analysis of the cancer biomarkers along with segmentation by indication, phase and geography
- Analysis of partnership deals from 2006 to 2010 along with segmentation by indication, deal type, geography and companies
- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Develop better strategies for cancer biomarkers research by understanding the market dynamics of the cancer biomarker research industry
- Develop market-entry and market expansion strategies by identifying the key cancer areas for high growth and high opportunities
- Understand the factors shaping the cancer biomarkers research market
- Reinforce R&D pipeline by identifying the key biomarker tests which can provide more accurate and early diagnosis of cancer
- Identify the key players best positioned to take the advantage of the opportunities in the global cancer biomarkers research market
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 GBI Research Report Guidance 8
3 Biomarkers Overview 9
3.1 History of Cancer Biomarkers 9
3.2 Use of Cancer Biomarkers 10
3.2.1 Screening and Early Detection 10
3.2.2 Diagnosis of Cancer 11
3.2.3 Prognosis and Measuring Effectiveness of Treatment 12
3.2.4 Detecting Recurrent Cancer 13
3.3 Efficiency of Cancer Biomarkers 14
3.3.1 Speed and Accuracy of Diagnosis 14
3.3.2 Optimize Costs 14
3.3.3 Increased Survival Rates 15
3.3.4 Non Invasive Techniques 15
3.4 Limitations of Cancer Biomarkers 16
3.5 Key Takeaway 16
4 Market Characterization 17
4.1 Market Overview 17
4.2 Market Size and Forecasts 17
4.2.1 Segmentation by Indication 19
4.3 Drivers and Restraints 29
4.3.1 Market Drivers 30
4.3.2 Market Barriers 31
4.4 Key Takeaway 31
5 Patent Analysis 32
5.1 Segmentation by Patent Type 32
5.2 Segmentation by Company 33
5.3 Segmentation by Geography 34
5.4 Key Takeaway 35
6 Pipeline Analysis 36
6.1 Biomarkers in Cancer Research – Pipeline by Indication 36
6.2 Biomarkers in Cancer Research – Pipeline by Phase 37
6.3 Biomarkers in Cancer Research – Pipeline by Geography 38
6.4 Key Takeaway 38
7 Competitive Landscape 39
7.1 Clarient, Inc. 39
7.1.1 Business Description 39
7.1.2 Pipeline 39
7.1.3 Major Products 40
7.1.4 Partnership and M&A Deals 40
7.2 Qiagen N.V. 41
7.2.1 Business Description 41
7.2.2 Pipeline 42
7.2.3 Major Products 42
7.2.4 Partnership and M&A Deals 44
7.3 Laboratory Corporation of America Holdings 46
7.3.1 Business Description 46
7.3.2 Pipeline 46
7.3.3 Major Products 46
7.3.4 Partnership and M&A Deals 47
7.4 bioMerieux S.A. 49
7.4.1 Business Description 49
7.4.2 Pipeline 49
7.4.3 Major Products 49
7.4.4 Partnership and M&A Deals 50
7.5 Biomoda, Inc. 52
7.5.1 Business Description 52
7.5.2 Pipeline 52
7.5.3 Major Products 52
7.5.4 Partnership and M&A Deals 53
7.6 Exiqon A/S 53
7.6.1 Business Description 53
7.6.2 Pipeline 54
7.6.3 Major Products 54
7.6.4 Partnership and M&A Deals 55
7.7 Beckman Coulter, Inc. 55
7.7.1 Business Description 55
7.7.2 Pipeline 55
7.7.3 Major Products 56
7.7.4 Partnership and M&A Deals 56
7.8 A&G Pharmaceutical, Inc. 57
7.8.1 Business Description 57
7.8.2 Pipeline 57
7.8.3 Major Products 58
7.8.4 Partnership and M&A Deals 58
7.9 AdnaGen AG 59
7.9.1 Business Description 59
7.9.2 Pipeline 59
7.9.3 Major Products 59
7.9.4 Partnership and M&A Deals 60
7.10 Rosetta Genomics, Ltd. 61
7.10.1 Business Description 61
7.10.2 Pipeline 62
7.10.3 Major Products 62
7.10.4 Partnership and M&A Deals 63
8 Deals Analysis 64
8.1 Partnership Deals 64
8.1.1 Partnership Deals by Year 64
8.1.2 Partnership Deals by Indication 65
8.1.3 Partnership Deals by Deal Type 66
8.1.4 Partnership Deals by Geography 67
8.1.5 Partnership Deals by Companies 68
8.2 M&A Landscape 69
8.2.1 M&A Deals by Value 69
8.2.2 M&A Deals by Geography 70
8.2.3 M&A Deals by Companies 71
8.2.4 Top Five M&A Deals by Value 71
8.3 Key Takeaway 73
9 Conclusion 74
10 Appendix 75
10.1 Market Definitions 75
10.2 Abbreviations 75
10.3 Research Methodology 76
10.3.1 Coverage 76
10.3.2 Secondary Research 77
10.3.3 Primary Research 77
10.3.4 Expert Panel Validation 77
10.4 Contact Us 78
10.5 Disclaimer 78
10.6 Sources 78
1.1 List of Tables
Table 1: Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016 18
Table 2: Biomarkers in Cancer Research, Global, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016 20
Table 3: Biomarkers in Cancer Research, Global, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016 21
Table 4: Biomarkers in Cancer Research, Global, Lung Cancer Biomarkers Market Revenues ($m), 2007–2016 22
Table 5: Biomarkers in Cancer Research, Global, Colorectal Cancer Biomarkers Market Revenues ($m), 2007–2016 23
Table 6: Biomarkers in Cancer Research, Global, Cervical Cancer Biomarkers Market Revenues ($m), 2007–2016 24
Table 7: Biomarkers in Cancer Research, Global, Head & Neck Cancer Biomarkers Market Revenues ($m), 2007–2016 25
Table 8: Biomarkers in Cancer Research, Global, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007–2016 26
Table 9: Biomarkers in Cancer Research, Global, Ovarian Cancer Biomarkers Market Revenues ($m), 2007–2016 27
Table 10: Biomarkers in Cancer Research, Global, Stomach Cancer Biomarkers Market Revenues ($m), 2007–2016 28
Table 11: Biomarkers in Cancer Research, Global, Patent Analysis by Company, 2010 33
Table 12: Biomarkers in Cancer Research, Global, Patent Analysis by Territory, 2010 34
Table 13: Biomarkers in Cancer Research, Global, Pipeline by Indication and Stage of Development, August 2010 36
Table 14: Biomarkers in Cancer Research, Clarient Pipeline, August 2010 39
Table 15: Biomarkers in Cancer Research, Clarient, Major M&A Deals, 2005–2010 40
Table 16: Biomarkers in Cancer Research, Clarient, Partnership Deals, 2006–2010 41
Table 17: Biomarkers in Cancer Research, Qiagen Pipeline, August 2010 42
Table 18: Biomarkers in Cancer Research, Qiagen, Major M&A Deals, 2005–2010 44
Table 19: Biomarkers in Cancer Research, Qiagen, Partnership Deals, 2006–2010 45
Table 20: Biomarkers in Cancer Research, Laboratory Corporation of America Holdings, Pipeline, August 2010 46
Table 21: Biomarkers in Cancer Research, Laboratory Corporation of America Holdings, Major M&A Deals, 2005–2010 47
Table 22: Biomarkers in Cancer Research, Laboratory Corporation of America Holdings, Partnership Deals, 2006–2010 48
Table 23: Biomarkers in Cancer Research, bioMerieux Pipeline, August 2010 49
Table 24: Biomarkers in Cancer Research, bioMerieux, Major M&A Deals, 2005–2010 50
Table 25: Biomarkers in Cancer Research, bioMerieux, Partnership Deals, 2006–2010 51
Table 26: Biomarkers in Cancer Research, Biomoda Pipeline, August 2010 52
Table 27: Biomarkers in Cancer Research, Biomoda, Partnership Deals, 2006–2010 53
Table 28: Biomarkers in Cancer Research, Exiqon Pipeline, August 2010 54
Table 29: Biomarkers in Cancer Research, Exiqon, Major M&A Deals, 2005–2010 55
Table 30: Biomarkers in Cancer Research, Beckman Coulter Pipeline, August 2010 55
Table 31: Biomarkers in Cancer Research, Beckman Coulter, Major M&A Deals, 2005–2010 56
Table 32: Biomarkers in Cancer Research, Beckman Coulter, Partnership Deals, 2006–2010 57
Table 33: Biomarkers in Cancer Research, A&G Pharmaceutical Pipeline, August 2010 57
Table 34: Biomarkers in Cancer Research, A&G Pharmaceutical, Major M&A Deals, 2005–2010 58
Table 35: Biomarkers in Cancer Research, AdnaGen Pipeline, August 2010 59
Table 36: Biomarkers in Cancer Research, AdnaGen, Major M&A Deals, 2005–2010 60
Table 37: Biomarkers in Cancer Research, AdnaGen, Partnership Deals, 2006–2010 61
Table 38: Biomarkers in Cancer Research, Rosetta Genomics Pipeline, August 2010 62
Table 39: Biomarkers in Cancer Research, Rosetta Genomics, Partnership Deals, 2006–2010 63
Table 40: Biomarkers in Cancer Research, Global, Partnership Deals by Indication, 2006–2010 65
1.2 List of Figures
Figure 1: Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016 17
Figure 2: Biomarkers in Cancer Research, Global, Market Segmentation by Indication, 2009 19
Figure 3: Biomarkers in Cancer Research, Global, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016 20
Figure 4: Biomarkers in Cancer Research, Global, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016 21
Figure 5: Biomarkers in Cancer Research, Global, Lung Cancer Biomarkers Market Revenues ($m), 2007–2016 22
Figure 6: Biomarkers in Cancer Research, Global, Colorectal Cancer Biomarkers Market Revenues ($m), 2007–2016 23
Figure 7: Biomarkers in Cancer Research, Global, Cervical Cancer Biomarkers Market Revenues ($m), 2007–2016 24
Figure 8: Biomarkers in Cancer Research, Global, Head & Neck Cancer Biomarkers Market Revenues ($m), 2007–2016 25
Figure 9: Biomarkers in Cancer Research, Global, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007–2016 26
Figure 10: Biomarkers in Cancer Research, Global, Ovarian Cancer Biomarkers Market Revenues ($m), 2007–2016 27
Figure 11: Biomarkers in Cancer Research, Global, Stomach Cancer Biomarkers Market Revenues ($m), 2007–2016 28
Figure 12: Biomarkers in Cancer Research, Market Drivers and Restraints, August 2010 29
Figure 13: Biomarkers in Cancer Research, Global, Patent Analysis by Patent Type, 2010 32
Figure 14: Biomarkers in Cancer Research, Global, Patent Analysis by Company, 2010 33
Figure 15: Biomarkers in Cancer Research, Global, Patent Analysis by Territory, 2010 34
Figure 16: Biomarkers in Cancer Research, Global, Pipeline by Indication (%), August 2010 36
Figure 17: Biomarkers in Cancer Research, Global, Pipeline by Phase of Development (%), August 2010 37
Figure 18: Biomarkers in Cancer Research, Global, Pipeline by Geography (%), August 2010 38
Figure 19: Biomarkers in Cancer Research, Global, Partnership Deals by Year, 2006–2010 64
Figure 20: Biomarkers in Cancer Research, Global, Partnership Deals by Indication, 2006–2010 65
Figure 21: Biomarkers in Cancer Research, Global, Partnership Deals by Deal Type, 2006–2010 66
Figure 22: Biomarkers in Cancer Research, Global, Partnership Deals by Geography, 2006–2010 67
Figure 23: Biomarkers in Cancer Research, Global, Partnership Deals by Companies, 2006–2010 68
Figure 24: Biomarkers in Cancer Research, Global, M&A Deals by Value (%), 2005–2010 69
Figure 25: Biomarkers in Cancer Research, Global, M&A Deals by Geography (%), 2005–2010 70
Figure 26: Biomarkers in Cancer Research, Global, M&A Deals by Companies (%), 2005–2010 71
Companies mentioned
Clarient, Inc.
Qiagen N.V.
Laboratory Corporation of America Holdings
bioMerieux S.A.
Biomoda, Inc.
Exiqon A/S
Beckman Coulter, Inc.
A&G Pharmaceutical, Inc.
AdnaGen AG
Rosetta Genomics, Ltd.
To order this report:
Pathology Industry: Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth
Check our Company Profile, SWOT and Revenue Analysis!
|
CONTACT: |
|
|
Nicolas Bombourg |
|
|
Reportlinker |
|
|
Email: [email protected] |
|
|
US: (805)652-2626 |
|
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker